Impact of cilostazol on intimal proliferation after directional coronary atherectomy
- 1 March 1998
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 135 (3) , 495-502
- https://doi.org/10.1016/s0002-8703(98)70327-8
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Pharmacologic Treatment of Intimal Hyperplasia After Metallic Stent Placement in the Peripheral ArteriesInvestigative Radiology, 1995
- Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomyThe American Journal of Cardiology, 1995
- Two Major Signal Pathways LinkedScience, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in CultureJournal of Cardiovascular Pharmacology, 1992
- Restenosis after coronary angioplasty: An overviewJournal of the American College of Cardiology, 1991
- PLATELET-DERIVED GROWTH FACTORThe Lancet, 1989
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- Percutaneous Transluminal Coronary Angioplasty in 1985–1986 and 1977–1981New England Journal of Medicine, 1988